...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Child and Adolescent Psychiatry and Mental Health >Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials
【24h】

Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

机译：儿童和青少年对阿托莫西汀治疗反应的差异以及与健康相关的生活质量与注意力缺陷/多动障碍的核心症状之间的相关性：五个阿托莫西汀试验的荟萃分析

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives To explore the influence of age on treatment responses to atomoxetine and to assess the relationship between core symptoms of attention deficit/hyperactivity disorder (ADHD) and health-related quality of life (HR-QoL) outcomes. Data Sources Data from five similar clinical trials of atomoxetine in the treatment of children and adolescents with ADHD were included in this meta-analysis. Study Selection Atomoxetine studies that used the ADHD Rating Scale (ADHD-RS) and the Child Health and Illness Profile Child Edition (CHIP-CE) as outcome measures were selected. Interventions Treatment with atomoxetine. Main Outcome Measures Treatment group differences (atomoxetine vs placebo) in terms of total score, domains, and subdomains of the CHIP-CE were compared across age groups, and correlations between ADHD-RS scores and CHIP-CE scores were calculated by age. Results Data of 794 subjects (611 children, 183 adolescents) were pooled. At baseline, adolescents showed significantly (p < 0.05) greater impairment compared with children in the Family Involvement, Satisfaction with Self, and Academic Performance subdomains of the CHIP-CE. Treatment effect of atomoxetine was significant in both age groups for the Risk Avoidance domain and its subdomains. There was a significant age-treatment interaction with greater efficacy seen in adolescents in both the Risk Avoidance domain and the Threats to Achievement subdomain. Correlations between ADHD-RS and CHIP-CE scores were generally low at baseline and moderate in change from baseline and were overall similar in adolescents and children. Conclusions Atomoxetine was effective in improving some aspects of HR-QoL in both age groups. Correlations between core symptoms of ADHD and HR-QoL were low to moderate.
机译：目的探讨年龄对阿托西汀治疗反应的影响，并评估注意缺陷/多动障碍（ADHD）的核心症状与健康相关的生活质量（HR-QoL）之间的关系。数据来源这项荟萃分析包括五项阿托莫西汀治疗儿童多动症儿童和青少年的类似临床试验的数据。研究选择选择使用多动症评分量表（ADHD-RS）和儿童健康和疾病概况儿童版（CHIP-CE）作为结果指标的Atomoxetine研究。干预用阿莫西汀治疗。主要结果衡量指标比较了不同年龄组的CHIP-CE总分，结构域和亚结构域之间的治疗组差异（atomoxetine与安慰剂），并按年龄计算了ADHD-RS得分与CHIP-CE得分之间的相关性。结果汇总了794名受试者（611名儿童，183名青少年）的数据。在基线时，在CHIP-CE的家庭参与，对自我的满意度和学业成绩子域中，与儿童相比，青少年表现出显着（p <0.05）更大的损害。对于风险规避域及其亚域，阿托莫西汀的治疗效果在两个年龄组中均显着。在“风险规避”领域和“成就威胁”子领域中，青少年之间存在显着的年龄-治疗相互作用，并具有更大的功效。 ADHD-RS和CHIP-CE评分之间的相关性通常在基线时较低，而与基线相比变化适中，在青少年中总体上相似。结论Atomoxetine在改善两个年龄组的HR-QoL方面均有效。多动症和HR-QoL核心症状之间的相关性是低到中度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号